Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
Zhongguo Ying Yong Sheng Li Xue Za Zhi ; 38(5): 406-411, 2022 Sep.
Article in Chinese | MEDLINE | ID: mdl-37088742

ABSTRACT

OBJECTIVE: In the present study, we determined whether the glycogen phosphorylase(GP)inhibitor 1,4-dideoxy-1,4-imino-D-arabinitol (DAB) ameliorates pentylenetetrazole (PTZ)-induced acute seizure, neuroinflammation and memory impairment in rats. METHODS: In experiment 1, rats were randomly divided into the Vehicle (n=5) and PTZ (n=5) groups, and received intraperitoneal injection of saline or PTZ (70 mg/kg), respectively. Hippocampal tissues were collected 30 min after drug injection. Western blot was used to examine the levels of GP expression. Colorimetric assay was used to determine the levels of lactate. In experiment 2, rats were randomly divided into the Vehicle+Vehicle (n=18), DAB+Vehicle (n=18), Vehicle+PTZ (n=19) and DAB+PTZ (n=18) groups. Rats received intracerebroventricular injection of PBS or DAB (50 µg/2 µl) 15 min before receiving intraperitoneal injection of saline or PTZ (70 mg/kg). Behavioural assays and the Racine scale were used to evaluate seizure severity. Western blot was used to examine the levels of targeted protein of hippocampal tissues. Novel object recognition test was used to assess memory performance. RESULTS: ① Compared with the Vehicle group, the levels of GP and lactate in the hippocampal tissues of the PTZ group were increased significantly (both P<0.01). ② Compared with the Vehicle+PTZ group, in the DAB+PTZ group, the levels of myoclonic body jerk latency, forelimb clonus latency and tonic-clonic seizure latency were increased significantly (all P<0.01), while the duration of seizure and seizure scores were decreased significantly (both P<0.01). ③ Compared with the Vehicle+Vehicle group, in the Vehicle +PTZ group, the levels of IL-1ß, IL-6, TNF-α, IBA-1 and GFAP in the hippocampal tissues were increased significantly (all P<0.01), and the discrimination index in the novel object recognition test was decreased significantly (P<0.01). Compared with the Vehicle+PTZ group, in the DAB+PTZ group, the levels of IL-1ß, TNF-α, IBA-1 and GFAP in the hippocampal tissues were decreased significantly (all, P<0.01), while the discrimination index in the novel object recognition test was increased significantly (P<0.01). CONCLUSION: DAB ameliorates PTZ-induced seizure, neuroinflammation and memory impairment in rats, suggesting that DAB may serve as a novel agent for potential clinical treatment of epilepsy.


Subject(s)
Glycogen Phosphorylase , Neuroinflammatory Diseases , Seizures , Animals , Rats , Anticonvulsants/adverse effects , Anticonvulsants/therapeutic use , Glycogen Phosphorylase/antagonists & inhibitors , Lactates/adverse effects , Neuroinflammatory Diseases/drug therapy , Pentylenetetrazole/adverse effects , Seizures/chemically induced , Seizures/complications , Tumor Necrosis Factor-alpha
2.
Neuropeptides ; 87: 102131, 2021 Jun.
Article in English | MEDLINE | ID: mdl-33640616

ABSTRACT

Apelin is an endogenous ligand of G protein-coupled receptor APJ. In recent years, many studies have shown that the apelin/APJ system has neuroprotective properties, such as anti-inflammatory, anti-oxidative stress, anti-apoptosis, and regulating autophagy, blocking excitatory toxicity. Apelin/APJ system has been proven to play a role in various neurological diseases and may be a promising therapeutic target for nervous system diseases. In this paper, the neuroprotective properties of the apelin/APJ system and its role in neurologic disorders are reviewed. Further understanding of the pathophysiological effect and mechanism of the apelin/APJ system in the nervous system will help develop new therapeutic interventions for various neurological diseases.


Subject(s)
Apelin Receptors/physiology , Apelin/physiology , Nervous System Diseases/physiopathology , Animals , Apelin/therapeutic use , Apoptosis/drug effects , Autophagy/drug effects , Brain Injuries, Traumatic/drug therapy , Brain Injuries, Traumatic/physiopathology , Epilepsy/drug therapy , Epilepsy/physiopathology , Humans , Inflammation , Ischemic Stroke/drug therapy , Ischemic Stroke/physiopathology , Mental Disorders/drug therapy , Mental Disorders/physiopathology , Mice , Models, Neurological , Neurodegenerative Diseases/drug therapy , Neurodegenerative Diseases/physiopathology , Neuroprotective Agents/therapeutic use , Neurotoxins/pharmacology , Oxidative Stress/drug effects , Pain Management , Peptide Fragments/pharmacology , Peptide Fragments/therapeutic use , Rats , Signal Transduction/drug effects , Signal Transduction/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...